On Oct 28, major Wall Street analysts update their ratings for $Avantor (AVTR.US)$, with price targets ranging from $25 to $28.
Morgan Stanley analyst Tejas Savant maintains with a buy rating, and adjusts the target price from $28 to $27.
Barclays analyst Luke Sergott maintains with a buy rating, and maintains the target price at $25.
Wells Fargo analyst Brandon Couillard maintains with a buy rating, and adjusts the target price from $30 to $28.
Baird analyst Catherine Ramsey Schulte maintains with a buy rating, and maintains the target price at $26.
Stifel analyst Daniel Arias maintains with a buy rating, and maintains the target price at $28.
Furthermore, according to the comprehensive report, the opinions of $Avantor (AVTR.US)$'s main analysts recently are as follows:
Avantor experienced a return to growth in LSS and Bioprocessing recovery, which was balanced out by weakness in U.S. semiconductor performance, according to an analysis shared with investors following the company's earnings release.
The firm expressed satisfaction with Avantor's robust free cash flow generation during the quarter and the gradual uptick in bioprocessing and equipment & instrumentation revenue, which surpassed expectations. Although management has not offered projections for 2025, the expectation is for a consistent, gradual enhancement throughout the fiscal year.
The softness in the semiconductor segment is overshadowing what is otherwise considered a 'solid' revenue outcome. Attention remains fixated on the EBITDA margin shortfall, casting doubts on the prospect of achieving a 20% EBITDA margin by the year 2025. It is anticipated that the company will approach this target, but it will necessitate a favorable product mix and additional cost reductions to attain it. Expectations for growth have been moderated to 3%, taking into account the semiconductor situation and margin outlook for 2025.
The firm indicated that Avantor's third quarter performance surpassed expectations, despite a notable weakness in the Semiconductor segment. The Bioprocess area showed strong results, while the Laboratory division experienced a modest improvement alongside robust cost management and Free Cash Flow generation.
Avantor's $12M revenue shortfall, primarily due to decreased sales in applied markets, was somewhat mitigated by stronger results in Lab Solutions and bioprocessing segments. Despite the revenue miss, there's a positive outlook on the stock's performance during downturns and confidence in the company's ability to meet its FY25 financial targets.
Here are the latest investment ratings and price targets for $Avantor (AVTR.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
